Differentiating Polycystic Ovary Syndrome from Adrenal Disorders

被引:16
作者
Yesiladali, Mert [1 ]
Yazici, Melis G. K. [1 ]
Attar, Erkut [1 ]
Kelestimur, Fahrettin [2 ]
机构
[1] Yeditepe Univ, Dept Obstet & Gynecol, Kozyatagi Hosp, TR-34854 Istanbul, Turkey
[2] Yeditepe Univ, Dept Endocrinol, Kosuyolu Hosp, TR-34718 Istanbul, Turkey
基金
英国医学研究理事会;
关键词
polycystic ovary syndrome; non-classical congenital adrenal hyperplasia; Cushing's syndrome; adrenal tumor; androgen excess disorder; LUTEINIZING-HORMONE; CUSHINGS-SYNDROME; ANDROGEN EXCESS; 21-HYDROXYLASE DEFICIENCY; INSULIN-RESISTANCE; BINDING GLOBULIN; OBESE WOMEN; HYPERPLASIA; TESTOSTERONE; DIAGNOSIS;
D O I
10.3390/diagnostics12092045
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although polycystic ovary syndrome (PCOS) is primarily considered a hyperandrogenic disorder in women characterized by hirsutism, menstrual irregularity, and polycystic ovarian morphology, an endocrinological investigation should be performed to rule out other hyperandrogenic disorders (e.g., virilizing tumors, non-classical congenital adrenal hyperplasia (NCAH), hyperprolactinemia, and Cushing's syndrome) to make a certain diagnosis. PCOS and androgen excess disorders share clinical features such as findings due to hyperandrogenism, findings of metabolic syndrome, and menstrual abnormalities. The diagnosis of a woman with these symptoms is generally determined based on the patient's history and rigorous clinical examination. Therefore, distinguishing PCOS from adrenal-originated androgen excess is an indispensable step in diagnosis. In addition to an appropriate medical history and physical examination, the measurement of relevant basal hormone levels and dynamic tests are required. A dexamethasone suppression test is used routinely to make a differential diagnosis between Cushing's syndrome and PCOS. The most important parameter for differentiating PCOS from NCAH is the measurement of basal and ACTH-stimulated 17-OH progesterone (17-OHP) when required in the early follicular period. It should be kept in mind that rapidly progressive hyperandrogenic manifestations such as hirsutism may be due to an androgen-secreting adrenocortical carcinoma. This review discusses the pathophysiology of androgen excess of both adrenal and ovarian origins; outlines the conditions which lead to androgen excess; and aims to facilitate the differential diagnosis of PCOS from certain adrenal disorders.
引用
收藏
页数:14
相关论文
共 82 条
  • [61] Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences
    Riestenberg, Carrie
    Jagasia, Anika
    Markovic, Daniela
    Buyalos, Richard P.
    Azziz, Ricardo
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02) : 575 - 585
  • [62] Clinical Evidence for Predominance of Delta-5 Steroid Production in Women with Polycystic Ovary Syndrome
    Rosencrantz, Marcus A.
    Coffler, Mickey S.
    Haggan, Annette
    Duke, Kimberly B.
    Donohue, Michael C.
    Shayya, Rana F.
    Su, H. Irene
    Chang, R. Jeffrey
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) : 1106 - 1113
  • [63] 17-HYDROXYPROGESTERONE RESPONSE TO BUSERELIN TESTING IN THE POLYCYSTIC-OVARY-SYNDROME
    SAHIN, Y
    KELESTIMUR, F
    [J]. CLINICAL ENDOCRINOLOGY, 1993, 39 (02) : 151 - 155
  • [64] The frequency of late-onset 21-hydroxylase and 11β-hydroxylase deficiency in women with polycystic ovary syndrome
    Sahin, Y
    Kelestimur, F
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 137 (06) : 670 - 674
  • [65] Sahin Y, 1997, HUM REPROD, V12, P910
  • [66] Differential diagnosis of clinically evident hyperandrogenism: experience with over 1000 consecutive patients.
    Sanchez, LA
    Knochenhauer, ES
    Gatlin, R
    Moran, C
    Azziz, R
    [J]. FERTILITY AND STERILITY, 2001, 76 (03) : S111 - S111
  • [67] Structural Insights into Aldosterone Synthase Substrate Specificity and Targeted Inhibition
    Strushkevich, Natallia
    Gilep, Andrei A.
    Shen, Limin
    Arrowsmith, Cheryl H.
    Edwards, Aled M.
    Usanov, Sergey A.
    Park, Hee-Won
    [J]. MOLECULAR ENDOCRINOLOGY, 2013, 27 (02) : 315 - 324
  • [68] A new contributing factor to polycystic ovary syndrome: The genetic variant of luteinizing hormones
    Tapanainen, JS
    Koivunen, R
    Fauser, BCJM
    Taylor, AE
    Clayton, RN
    Rajkowa, M
    White, D
    Franks, S
    Anttila, L
    Pettersson, KSI
    Huhtaniemi, IT
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (05) : 1711 - 1715
  • [69] Cushing syndrome: Old and new genes
    Tatsi, Christina
    Flippo, Chelsi
    Stratakis, Constantine A.
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 34 (02)
  • [70] Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome
    Taylor, AE
    McCourt, B
    Martin, KA
    Anderson, EJ
    Adams, JM
    Schoenfeld, D
    Hall, JE
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) : 2248 - 2256